Sword Bio Appoints John Moriarity as Vice President, Business Development, East Coast
Sword Bio (“Sword”), a contract research organization that supports biotech and pharmaceutical companies with their bioanalytical needs for pre-clinical and clinical trials, announces the appointment of John Moriarity VP, Business Development, East Coast.
John brings more than 20 years of biopharma experience to Sword Bio, with a career that began in the laboratory and evolved into leading commercial strategy across the bioanalytical services landscape. He is known for bridging scientific depth with commercial execution, helping biotech and pharmaceutical partners navigate complex bioanalytical challenges with clarity and speed. John has consistently driven growth by building high accountability teams, expanding into new markets, and aligning technical capabilities with real program risk. He has held leadership roles at Covance, BioAgilytix, and Prolytix, and most recently served as Senior Vice President of North American Bioanalytical Sales at ALIRI Bio.
“We’re thrilled to welcome John to the team,” said David Dingott, CEO. “He brings a unique combination of scientific insight and commercial leadership that aligns perfectly with how we support our partners. John is known for building meaningful partnerships and helping his clients navigate complex program requirements. His approach to aligning strategy with real program needs will be a valuable addition as we continue to expand our presence on the East Coast.”
“Sword Bio’s commitment to acting as a true partner and extension of its clients’ teams aligns perfectly with my philosophy,” said John Moriarity. “I look forward to engaging on the specific needs and risks of each program to ensure bioanalytical data is fully prepared to support critical development decisions and advance programs with confidence.”
About Sword
Sword Bio is a leading bioanalytical CRO supporting biotech and pharmaceutical companies with research-grade assays, GLP pre-clinical and clinical assay development, validation, and sample analysis. Our core focus is on PK, Immunogenicity and Biomarker services.
Sword’s team is comprised of industry-experienced scientists and QA experts ensuring the highest levels of science, data integrity, and regulatory compliance through all phases of clinical development.
Sword has built an innovative process that offers its partners minimum lead times, no project minimums, transparency, communication, and white-glove service so that our clients can quickly achieve their goals.
For more information, visit www.swordbio.com